Loading...
Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
18.4%7D
2.2%1Y
18.4%7D
2.2%You can edit this narrative until Jun 30 10:08 PM. Then, changes will post as Updates.
You can edit this narrative until Jun 30 10:08 PM. Then, changes will post as Updates.